Blood microRNA markers to predict rejection in children with heart transplants
Studies blood microRNAs that may signal rejection or infection in children with transplanted hearts.
Plain-language title generated from the registry record
Registry title: Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs
Key facts
- Where
- Ann Arbor, Aurora, Chicago, Houston, Nashville, New York, and Pittsburgh, United StatesSee the 7 sites
Where in United States
- University of MichiganAnn Arbor, United StatesTaking people
- Children's Hospital ColoradoAurora, United StatesTaking people
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesTaking people
- Texas Children's HospitalHouston, United StatesTaking people
- Vanderbilt UniversityNashville, United StatesTaking people
- Columbia UniversityNew York, United StatesTaking people
- University of PittsburghPittsburgh, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Northwestern University
- Trial code
- NCT06532890
- Record updated
- 25 August 2026
- Original description
This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.Read full original descriptionShow less
Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs
This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.
Inclusion: Age ≤ 18 years at time of transplant listing; Subject is within 10-50 days post-orthotopic heart transplant at time of enrollment; Planned follow-up at the transplant center for a minimum of one-year; Caregiver able and willing to comply with the study visit schedule, study procedures, and study requirements.
Exclusion: Recipient of a multi-organ transplant; History of prior solid organ transplant before the index heart transplant; Ongoing mechanical circulatory support or hemodynamic instability after transplant; Active infection requiring either a) hospitalization or b) treatment with antimicrobial drugs (does not include prophylaxis for infection or suppressive antibiotics given after transplant); History of treated rejection prior to study enrollment; Inability to collect specified blood volume after enrollment and prior to 50 days post-transplant.